Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.

Inclusion Criteria: 1. Adults 19 years of age or older 2. Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion 3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance Exclusion Criteria 1. Patients with hypersensitivity to any ingredients of this drug 2. Patients who intend to use this drug for non-approved indications 3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug